L. Büdi

Capecitabine in Combination with Docetaxel in First Line in HER2-Negative Metastatic Breast Cancer: an Observational Study

E. Hitre, Z. Horváth, J. Erfán, 2017, Pathology & Oncology Research.

Factors affecting prognosis in patients treated with bevacizumab plus paclitaxel as first-line chemotherapy for HER2-negative metastatic breast cancer: an international pooled analysis of individual patient data from four prospective observational studies

A. Schneeweiss, O. Gluz, H. Yamashiro, 2022, Breast Cancer.

Factors affecting prognosis in patients treated with bevacizumab plus paclitaxel as first-line chemotherapy for HER2-negative metastatic breast cancer: an international pooled analysis of individual patient data from four prospective observational studies

A. Schneeweiss, O. Gluz, H. Yamashiro, 2022, Breast Cancer.